Table 3 Effects of atomoxetine/oxybutynin use on the risk of obstructive sleep apnea.

1

No use

26,820

78

340,161.37

22.93

Reference

Either monotherapy or AOC

8940

25

114,053.98

21.92

0.846

0.517

1.934

0.243

2

No use

26,820

78

340,161.37

22.93

Reference

Atomoxetine only

4301

13

48,121.81

27.01

1.264

0.862

2.894

0.392

Oxybutynin only

4502

10

53,454.01

18.71

0.782

0.503

1.880

0.241

AOC

137

2

12,478.16

16.03

0.466

0.264

1.307

0.181

3

No use

26,820

78

340,161.37

22.93

Reference

Either monotherapy or AOC, 30–365 days

2,75

16

47,505.07

33.68

1.463

0.672

2.565

0.711

Either monotherapy or AOC, ≥ 366 days

5965

9

66,548.91

13.52

0.401

0.222

0.997

0.049

4

No use

26,820

78

340,161.37

22.93

Reference

Atomoxetine only, 30–365 days

1312

9

21,101.78

42.65

2.067

0.975

4.121

0.896

Atomoxetine only, ≥ 366 days

2989

4

27,020.03

14.80

0.438

0.330

1.996

0.245

Oxybutynin only, 30–365 days

1583

6

21,981.04

27.30

1.385

0.904

2.670

0.332

Oxybutynin only, ≥ 366 days

2919

4

31,472.97

12.71

0.307

0.204

0.995

0.045

AOC, 30–365 days

80

1

4422.25

22.61

1.154

0.892

1.501

0.197

AOC, ≥ 366 days

57

1

8055.91

12.41

0.299

0.102

0.933

0.002